Impact of adherence to statins on chronic heart failure in primary prevention.

AIMS Statins are effective in the prevention of an atherosclerotic event, e.g. coronary artery disease and cerebrovascular disease. Patients at high risk of cardiovascular disease (CVD), such as chronic heart failure (CHF), might benefit from the effects of statin therapy. However, one question that has not yet been answered and that may clarify the role of statins in CHF is whether statins prevent the development of CHF in patients with a low risk of CVD. Our aim was to evaluate the impact of adherence to statins on the incidence of CHF. METHODS A cohort of 111,481 patients was reconstructed using the Régie de l'Assurance Maladie du Québec databases. Patients were eligible if they were between 45 and 85 years old, without CVD, and newly treated with statins between 1999 and 2004. A nested case-control design was used to study CHF. Every case of CHF was matched for age and duration of follow-up in up to 15 randomly selected controls. The adherence level was measured by calculating the medication possession ratio. Rate ratios (RR) of CHF were estimated by conditional logistic regression adjusting for several covariables. RESULTS The mean patient age was 63 years, 49% had hypertension, 21% had diabetes and 41% were male. A high level of adherence to statins was associated with a reduction of CHF (RR 0.81; 0.71, 0.91). The risks associated with CHF were the development of CVD during follow-up, being a social-aid recipient, and suffering from hypertension, diabetes mellitus, or having a higher chronic disease score. CONCLUSION Our study indicates that better adherence to statins is associated with a reduced risk of CHF.

[1]  A. Jánosi,et al.  Rosuvastatin in older patients with systolic heart failure. , 2007, The New England journal of medicine.

[2]  Sander Greenland,et al.  Monte Carlo sensitivity analysis and Bayesian analysis of smoking as an unmeasured confounder in a study of silica and lung cancer. , 2004, American journal of epidemiology.

[3]  A. Go,et al.  Gender and risk of adverse outcomes in heart failure. , 2004, The American journal of cardiology.

[4]  J. Larosa,et al.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.

[5]  B. Stricker,et al.  Confounding by indication: an example of variation in the use of epidemiologic terminology. , 1999, American journal of epidemiology.

[6]  S. Sunwoo,et al.  Determinants of non‐compliance with lipid‐lowering therapy in hyperlipidemic patients , 2002, Pharmacoepidemiology and drug safety.

[7]  D. Mozaffarian,et al.  The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. , 2005, The American journal of cardiology.

[8]  D. Levy,et al.  The epidemiology of heart failure: the Framingham Study. , 1993, Journal of the American College of Cardiology.

[9]  R Peto,et al.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.

[10]  D. Mozaffarian,et al.  Statin therapy is associated with lower mortality among patients with severe heart failure. , 2004, The American journal of cardiology.

[11]  A J Belanger,et al.  Epidemiology of heart failure. , 1991, American heart journal.

[12]  D. Waters,et al.  Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure: Subgroup Analysis of the Treating to New Targets (TNT) Study , 2007, Circulation.

[13]  M. McDermott,et al.  Impact of medication nonadherence on coronary heart disease outcomes. A critical review. , 1997, Archives of internal medicine.

[14]  P. Giral,et al.  Factors associated with low compliance with lipid‐lowering drugs in hyperlipidemic patients , 2000, Journal of clinical pharmacy and therapeutics.

[15]  S. Dimauro,et al.  Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. , 2004, Archives of neurology.

[16]  Michael Böhm,et al.  Statins in the Treatment of Chronic Heart Failure: A Systematic Review , 2006, PLoS medicine.

[17]  A. Go,et al.  Statin therapy and risks for death and hospitalization in chronic heart failure. , 2006, JAMA.

[18]  S. Anker,et al.  The endotoxin-lipoprotein hypothesis , 2000, The Lancet.

[19]  R. Herings,et al.  Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. , 2006, European heart journal.

[20]  Statin use and survival outcomes in elderly patients with heart failure. , 2005 .

[21]  R. Tamblyn,et al.  The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec. , 1995, Journal of clinical epidemiology.

[22]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[23]  Femida Gwadry-Sridhar,et al.  A checklist for medication compliance and persistence studies using retrospective databases. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[24]  R Tamblyn,et al.  Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment. , 2000, Journal of clinical epidemiology.

[25]  E H Wagner,et al.  A chronic disease score from automated pharmacy data. , 1992, Journal of clinical epidemiology.

[26]  Rishi Sikka,et al.  Estimating medication persistency using administrative claims data. , 2005, The American journal of managed care.

[27]  S Greenland,et al.  Sensitivity Analysis, Monte Carlo Risk Analysis, and Bayesian Uncertainty Assessment , 2001, Risk analysis : an official publication of the Society for Risk Analysis.

[28]  J. Tu,et al.  Class effects of statins in elderly patients with congestive heart failure: a population-based analysis. , 2008, American heart journal.

[29]  Krista F Huybrechts,et al.  Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. , 2006, Bone.

[30]  S. Lerakis,et al.  Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. , 2006, Journal of the American College of Cardiology.

[31]  L. Osterberg,et al.  Adherence to medication. , 2005, The New England journal of medicine.

[32]  S. Dimmeler,et al.  Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. , 2005, Kidney international.

[33]  M. Pfeffer,et al.  Ventricular Remodeling After Myocardial Infarction: Experimental Observations and Clinical Implications , 1990, Circulation.

[34]  D. Levy,et al.  Survival After the Onset of Congestive Heart Failure in Framingham Heart Study Subjects , 1993, Circulation.

[35]  J. Foody,et al.  Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function. , 2008, The American journal of cardiology.

[36]  S. Yusuf,et al.  Natural history and patterns of current practice in heart failure , 1993 .

[37]  M. Joffres,et al.  Knowledge and awareness of risk factors for cardiovascular disease among Canadians 55 to 74 years of age: results from the Canadian Heart Health Surveys, 1986-1992. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[38]  R. Bonow,et al.  Chronic heart failure in the United States: a manifestation of coronary artery disease. , 1998, Circulation.

[39]  Michal Abrahamowicz,et al.  Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure , 2005 .

[40]  W. Kannel,et al.  Incidence and Epidemiology of Heart Failure , 2000, Heart Failure Reviews.

[41]  V. Starc,et al.  Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. , 2005, Journal of cardiac failure.

[42]  R. Brook,et al.  Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. , 2006, Journal of the American College of Cardiology.

[43]  P. Poole‐Wilson,et al.  Coronary artery disease as the cause of incident heart failure in the population. , 2001, European heart journal.

[44]  Joanna M. Young,et al.  Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure. , 2005, Atherosclerosis.

[45]  Elinor Miller,et al.  Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). , 2003, The American journal of cardiology.

[46]  J. Cohn,et al.  Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT. , 2007, International journal of cardiology.

[47]  D. J. Veldhuisen,et al.  Heart failure and statins—Why do we need a clinical trial? , 2005, Zeitschrift für Kardiologie.

[48]  C. Stefanadis,et al.  Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. , 2005, Atherosclerosis.

[49]  R. Tamblyn,et al.  Validation of diagnostic codes within medical services claims. , 2004, Journal of clinical epidemiology.

[50]  J H Lubin,et al.  Biased selection of controls for case-control analyses of cohort studies. , 1984, Biometrics.

[51]  G. Fonarow,et al.  Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. , 2003, Journal of the American College of Cardiology.

[52]  C. Behl,et al.  Selenoprotein synthesis and side-effects of statins , 2004, The Lancet.

[53]  W. W. Muir,et al.  Regression Diagnostics: Identifying Influential Data and Sources of Collinearity , 1980 .

[54]  M. Kendrach,et al.  Approximate Equivalent Rosuvastatin Doses for Temporary Statin Interchange Programs , 2004, The Annals of pharmacotherapy.

[55]  F. McAlister,et al.  Lipid-Lowering Therapy and Outcomes in Heart Failure , 2007, Journal of cardiovascular pharmacology and therapeutics.

[56]  W. Kannel,et al.  The natural history of congestive heart failure: the Framingham study. , 1971, The New England journal of medicine.